Estudo randomizado | Segurança e eficácia da AGN-190584 em pessoas com presbiopia.

Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial – JAMA Ophthalmology

Comentário no Twitter

A new proprietary formulation of pilocarpine developed to treat presbyopia met its primary endpoint in the GEMINI phase 3 clinical trial, safely and effectively improving distance-corrected mesopic near vision for hours after eye drop instillation. https://t.co/WG5DZ6XQxZ pic.twitter.com/YXnW387R7i

— JAMAOphthalmology (@JAMAOphth) March 4, 2022